Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 3, Issue : 4, Year : 2017
Article Page : 476-479
Abstract
Objective: To study the variations, changes and rate of progression in the fundus findings of patients having diabetes and hypertension both, and to compare these findings from those having diabetes alone.
Result: FFA was done on total 30 patients, which were divided into two groups A and B there was male dominance (17. 56.6%). Majority of patients are in 50-70yr. age group. In group A, only 2 patients had Type-1 diabetes, rest had Type-2. In group A., maximum patient had history of duration of 20-60yr. where as in group B it is 10-20yr. In both groups mostly patients were on irregular treatment. Main FFA findings in both groups are Micro aneurysms and hard exudates, Hypertension was significantly related to retinopathy and both systolic and diastolic blood pressures were deemed to have an association.
Keywords: Hard exudates, Fundus fluorescein angiography, Microaneurysm
How to cite : Agarwal S, Singh S, Fundus fluorescein angiography in patients having diabetes with hypertension- An evaluation. Indian J Clin Exp Ophthalmol 2017;3(4):476-479
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.